GSK plc (LON:GSK) Receives Consensus Rating of “Hold” from Brokerages

Shares of GSK plc (LON:GSK) have been given an average recommendation of “Hold” by the seven research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is GBX 2,034.29.

Several brokerages have recently issued reports on GSK. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research report on Thursday, March 26th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research note on Tuesday, April 14th. Citigroup cut their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 1,900 price target on shares of GSK in a research note on Wednesday. Finally, Shore Capital Group reiterated a “buy” rating on shares of GSK in a research note on Wednesday, March 25th.

Insider Transactions at GSK

In other news, insider Jonathan Symonds purchased 5,000 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was bought at an average price of GBX 1,951 per share, for a total transaction of £97,550. Also, insider Wendy Becker purchased 4,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The shares were purchased at an average price of GBX 1,963 per share, with a total value of £78,520. In the last 90 days, insiders bought 9,619 shares of company stock worth $19,452,794. 0.20% of the stock is owned by company insiders.

GSK Trading Down 0.7%

Shares of GSK stock opened at GBX 1,926 on Thursday. GSK has a 1 year low of GBX 1,288.61 and a 1 year high of GBX 2,282. The firm has a market cap of £76.88 billion, a PE ratio of 13.55, a P/E/G ratio of 1.24 and a beta of 0.30. The stock has a fifty day moving average price of GBX 2,004.93 and a 200-day moving average price of GBX 1,950.73. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73.

GSK (LON:GSK) last announced its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The firm had revenue of GBX 762.90 billion during the quarter. Equities research analysts anticipate that GSK will post 175.980975 EPS for the current year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.